Catalyst Pharmaceuticals' Firdapse delivers strong growth with a 37% CAGR. Click here to find out why CPRX stock is a Hold.

Following this, Santhera has already started launch preparations for AGAMREE in the UK and expect first sales in this quarter. AGAMREE is the first and only medicinal product for DMD to have ...

Total Revenues of $491.7 Million, Marking Another Year of Record GrowthFull Year 2024 Total Revenues Grew 23.5% YoY, Driven by ...

The announcement follows finalised recommendations this week that backed Agamree (vamorolone) as a treatment for patients aged four and over with DMD from the National Institute for Health and ...

Santhera has reached an agreement with health insurance funds in Germany on reimbursement of its Agamree treatment for Duchenne muscular dystrophy (DMD) that should support broad use of the drug.

Shares of drugmaker Catalyst Pharmaceuticals (NASDAQ: CPRX) are up a little more than 8% as of midday on Thursday, down ...

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 ...

The company said, “For full year 2025, the Company expects total revenues to be between $545 million and $565 million, reflecting continued ...

Revenues generated from the sale of the newly launched muscle disease drug, Agamree (vamorolone), also contributed to the top line. The stock gained 5.9% in the after-market hours on Feb. 27 as ...

The fourth quarter alone saw revenues of $141.8 million, marking a 28.3% increase from the previous year, attributed to sustained growth in existing products and the successful launch of AGAMREE.

“Our record 2024 performance is a reflection of Catalyst’s successful launch of AGAMREE and our continued outstanding commercial capabilities that fuel the momentum of our existing products ...